Clinical Trial Update: Evaluating the Utility of the Apoptosis Imaging Biomarker 18F]ML10 in Patients With Non-Hodgkin's Lymphoma(NHL) [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the apoptosis imaging biomarker 18F]ML10 in patients with non-Hodgkin's lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• 18F]ML10

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cancer | Phase 1 | Status: TERMINATED